Welcome to our dedicated page for Cellectis S.A. American Depositary Shares news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis S.A. American Depositary Shares stock.
Cellectis S.A. (symbol: CLLS) is a clinical-stage biopharmaceutical company that specializes in developing cutting-edge cancer immunotherapies using gene-edited T-cells, known as UCART. With over 18 years of experience in gene editing, Cellectis leverages its proprietary TALEN® technology and PulseAgile electroporation system to harness the power of the immune system to combat cancer.
Cellectis is dedicated to creating innovative products in the fields of immuno-oncology and beyond. Its portfolio includes allogeneic Chimeric Antigen Receptor T-cells (CAR-T) product candidates and gene-edited hematopoietic stem and progenitor cells (HSPC) for various therapeutic applications.
Recent achievements include advancements in gene correction and gene insertion technologies, presented at esteemed scientific conferences. For instance, the company has introduced a novel method for circularizing non-viral single-strand DNA templates, enhancing gene editing outcomes in HSPCs. Cellectis is also collaborating with renowned pharmaceutical companies like AstraZeneca, further expanding its pipeline of allogeneic CAR T-cell therapies.
Financially, Cellectis is listed on both the NASDAQ (ticker: CLLS) and the NYSE Alternext (ticker: ALCLS) markets. The company's ongoing projects and research efforts are supported by robust investment and partnership agreements, showcasing its commitment to improving health outcomes through innovative biotechnological solutions.
For more information, visit the company's website at www.cellectis.com.
Cellectis has released its monthly update on share capital and voting rights as of May 31, 2024. The company, listed on Euronext Growth with ISIN code FR0010425595, reports a total of 100,093,635 shares in its capital. The number of voting rights stands at 88,029,374. For more details, media and investor relations contacts are provided.
Cellectis announced that the European Commission granted Orphan Drug Designation (ODD) to UCART22, its allogeneic CAR T product for treating Acute Lymphoblastic Leukemia (ALL).
UCART22 targets CD22 and is being evaluated in the Phase 1/2 BALLI-01 study, focusing on patients with relapsed/refractory ALL.
ALL accounts for 12% of all leukemia cases and progresses rapidly. The 10-year prevalence in the EU is estimated at 1.9 per 100,000 persons.
The ODD was based on preliminary clinical data showing UCART22's significant benefit in heavily pretreated patients. In December 2023, Cellectis reported encouraging data with a 67% response rate at Dose Level 2 for UCART22-P2.
ODD provides regulatory, financial, and commercial incentives.
Cellectis (Euronext Growth: ALCLS, NASDAQ: CLLS), a clinical-stage biotechnology company, will hold its annual general meeting on June 28, 2024, at 2:30 p.m. CET.
The meeting will take place at the Biopark auditorium, 11 rue Watt, 4th floor, 75013 Paris, France.
Details regarding the agenda and participation are available on the Cellectis website.
Cellectis reported its Q1 2024 financial results revealing key business updates and financial highlights. Key points include:
Completion of a $140M equity investment by AstraZeneca, pushing the company's cash position to $143M as of March 31, 2024, and extending its cash runway projection into 2026.
Revenues for Q1 2024 were $6.5M, a significant increase from $3.6M in Q1 2023.
R&D expenses rose to $22.3M from $21.1M, while SG&A expenses were relatively stable at $5.1M.
The company recorded a consolidated net income of $5.6M, compared to a net loss of $30.1M in Q1 2023.
Key clinical programs BALLI-01, NATHALI-01, and AMELI-01 continue to progress with updates expected by year-end 2024.
The appointment of Arthur Stril as Interim CFO was announced, and AstraZeneca now owns approximately 44% of Cellectis' share capital.
Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company specializing in gene-editing platform technologies, will announce its first quarter 2024 financial results on May 28, 2024, after the US market closes. The results will cover the period ending March 31, 2024. Following the announcement, the Company will hold an investor conference call and webcast on May 29, 2024, at 8:00 AM ET / 2:00 PM CET to discuss the financial results and provide an update on business activities. Investors and stakeholders can join the call using the provided domestic and international dial-in numbers or access the webcast online.
On May 16, 2024, Cellectis released its monthly update on share capital and voting rights as stipulated by Article 223-16 of the French financial markets authority. The company, listed on Euronext Growth under the ISIN code FR0010425595, reported a total of 99,955,535 shares in its capital and 87,891,239 voting rights as of May 3, 2024. For more details, the company provided contact information for their media and investor relations teams.
In a recent press release, Cellectis provided information on their share capital and company voting rights for April 30, 2024. The total number of shares in the capital was reported as 71,955,535 with a total number of voting rights at 77,891,229. This data was disclosed in compliance with Article 223-16 of the General Regulation of the French financial markets authority.
Cellectis announced the completion of an additional equity investment of $140M by AstraZeneca. AstraZeneca purchased 10,000,000 class A convertible preferred shares and 18,000,000 class B convertible preferred shares at $5.00 per share. This move solidifies AstraZeneca's ownership in Cellectis, giving them approximately 44% of the share capital and 30% of the voting rights in the company.
Cellectis appointed Arthur Stril as the interim Chief Financial Officer, replacing Bing Wang. Mr. Stril, with a strong background in finance and business development, will oversee finance, investor relations, and business development functions. His appointment comes at a critical growth phase for Cellectis, as they advance their pipeline of assets and explore new opportunities.
Cellectis reported financial results for the fourth quarter and full year 2023, highlighting key events like clinical study updates, strategic collaborations with AstraZeneca, and cash position. The company remains focused on advancing its Phase 1 clinical trials, presenting promising data on UCART22 and UCART20x22 at the ASH conference. The collaboration with AstraZeneca aims to develop innovative cell and gene therapies. Financially, Cellectis saw a significant increase in cash position to $156 million as of December 31, 2023.
FAQ
What is the current stock price of Cellectis S.A. American Depositary Shares (CLLS)?
What is the market cap of Cellectis S.A. American Depositary Shares (CLLS)?
What does Cellectis S.A. specialize in?
What proprietary technologies does Cellectis use?
What are UCART cells?
What recent advancements has Cellectis made?
Which companies has Cellectis partnered with?
On which stock markets is Cellectis listed?
What are HSPCs?
How long has Cellectis been in the gene editing field?
Where can I find more information about Cellectis?
How does Cellectis contribute to immuno-oncology?
